# Tevimbra (tislelizumab-jsgr) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tislelizumab-jsgr

> The FDA approved Tevimbra (tislelizumab-jsgr), sponsored by BeOne Medicines Ltd. (ONC), on March 3, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Tevimbra (tislelizumab-jsgr) |
| Codes |  |
| Sponsor | BeOne Medicines Ltd. (ONC) https://sec-api.dev/companies/onc/catalysts |
| Indications | To treat unresectable or metastatic esophageal squamous cell carcinoma, same proposed indication |
| Modality | biologic |
| FDA designations | priority review |

## Timeline

### March 13, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat unresectable or metastatic esophageal squamous cell carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Tevimbra | tislelizumab-jsgr | 3/13/2024 | To treat unresectable or metastatic esophageal squamous cell carcinomaDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024
- openFDA Drugs@FDA: "BLA761232 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20240313, review_priority STANDARD; sponsor_name BEIGENE; product TEVIMBRA (TISLELIZUMAB-JSGR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761232%22

### September 26, 2024: FDA advisory committee meeting

- Status: completed. Date confidence: exact. Indication: same proposed indication.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA advisory committee calendar: "The Committee will also discuss BLA 761417 for tislelizumab injection, submitted by BeiGene USA, Inc., for the same proposed indication." https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-26-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-09262024
- FDA advisory committee calendar: "The Committee will also discuss the new BLA 761380 for tislelizumab, submitted by BeiGene USA, Inc., for the same proposed indication." https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-26-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-09262024

### December 26, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761417 ORIG-1 (Type 9 - New indication submitted as distinct BLA, consolidated): submission_status AP, submission_status_date 20241226, review_priority STANDARD; sponsor_name BEIGENE; product TEVIMBRA (TISLELIZUMAB-JSGR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761417%22

### March 3, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-16T22:20:01.192Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761380 ORIG-1 (Type 9 - New indication submitted as distinct BLA, consolidated): submission_status AP, submission_status_date 20250303, review_priority STANDARD; sponsor_name BEIGENE; product TEVIMBRA (islelizumab-jsgr)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761380%22

### April 22, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761232 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20250422, review_priority STANDARD; sponsor_name BEIGENE; product TEVIMBRA (TISLELIZUMAB-JSGR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761232%22
- openFDA Drugs@FDA: "BLA761232 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20250422, review_priority STANDARD; sponsor_name BEIGENE; product TEVIMBRA (TISLELIZUMAB-JSGR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761232%22
- openFDA Drugs@FDA: "BLA761232 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20250422, review_priority STANDARD; sponsor_name BEIGENE; product TEVIMBRA (TISLELIZUMAB-JSGR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761232%22
- openFDA Drugs@FDA: "BLA761232 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20250422, review_priority STANDARD; sponsor_name BEIGENE; product TEVIMBRA (TISLELIZUMAB-JSGR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761232%22
- openFDA Drugs@FDA: "BLA761232 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20250422, review_priority STANDARD; sponsor_name BEIGENE; product TEVIMBRA (TISLELIZUMAB-JSGR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761232%22
- openFDA Drugs@FDA: "BLA761232 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20250422, review_priority STANDARD; sponsor_name BEIGENE; product TEVIMBRA (TISLELIZUMAB-JSGR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761232%22

### December 9, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761232 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20251209, review_priority STANDARD; sponsor_name BEIGENE; product TEVIMBRA (TISLELIZUMAB-JSGR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761232%22
- openFDA Drugs@FDA: "BLA761232 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20251209, review_priority STANDARD; sponsor_name BEIGENE; product TEVIMBRA (TISLELIZUMAB-JSGR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761232%22
- openFDA Drugs@FDA: "BLA761232 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20251209, review_priority STANDARD; sponsor_name BEIGENE; product TEVIMBRA (TISLELIZUMAB-JSGR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761232%22

### August 25, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761232 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20260825, review_priority PRIORITY; sponsor_name BEIGENE; product TEVIMBRA (TISLELIZUMAB-JSGR)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761232%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tislelizumab-jsgr.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Tevimbra (tislelizumab-jsgr) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tislelizumab-jsgr

```bibtex
@misc{secapidev_pdufa_tislelizumab_jsgr_20261116,
  title        = {Tevimbra (tislelizumab-jsgr) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tislelizumab-jsgr}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tislelizumab_jsgr_20261116","title":"Tevimbra (tislelizumab-jsgr) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tislelizumab-jsgr","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
